Total Payments
$76,257
2024 Payments
$1,413
Companies
33
Transactions
536
Medicare Patients
2,149
Medicare Billing
$185,336
Payment Breakdown by Category
Research$66,410 (87.1%)
Food & Beverage$9,727 (12.8%)
Education$119.49 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $66,410 | 31 | 87.1% |
| Food and Beverage | $9,727 | 501 | 12.8% |
| Education | $119.49 | 4 | 0.2% |
Payments by Type
Research
$66,410
31 transactions
General
$9,847
505 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $18,081 | 21 | $0 (2021) |
| Glenmark Pharmaceuticals Inc. | $13,700 | 3 | $0 (2017) |
| Genentech, Inc. | $13,631 | 5 | $0 (2019) |
| Circassia Pharmaceuticals Inc | $10,918 | 5 | $0 (2017) |
| Greer Laboratories, Inc. | $7,835 | 5 | $0 (2018) |
| Lupin Inc. | $2,500 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $2,041 | 92 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,750 | 118 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,018 | 44 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $922.07 | 56 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,413 | 62 | Regeneron Healthcare Solutions, Inc. ($253.62) |
| 2023 | $1,232 | 55 | AstraZeneca Pharmaceuticals LP ($317.97) |
| 2022 | $2,019 | 102 | AstraZeneca Pharmaceuticals LP ($457.68) |
| 2021 | $1,383 | 74 | GlaxoSmithKline, LLC. ($285.58) |
| 2020 | $1,075 | 66 | GlaxoSmithKline, LLC. ($297.05) |
| 2019 | $1,965 | 58 | Teva Pharmaceuticals USA, Inc. ($1,055) |
| 2018 | $16,731 | 69 | Greer Laboratories, Inc. ($7,835) |
| 2017 | $50,439 | 50 | Glenmark Pharmaceuticals Inc. ($13,700) |
All Payment Transactions
536 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $1.67 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: RESPIRATORY | ||||||
| 10/17/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Immunology and Neurology | ||||||
| 10/15/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Respiratory | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $9.55 | General |
| Category: RESPIRATORY | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 08/21/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: RESPIRATORY | ||||||
| 08/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Immunology | ||||||
| 08/12/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: BIOLOGIC | ||||||
| 07/31/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Immunology | ||||||
| 07/30/2024 | Hikma Pharmaceuticals USA | Ryaltris (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 07/16/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Pulmonology | ||||||
| 07/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Respiratory | ||||||
| 06/21/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Respiratory | ||||||
| 06/18/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Inflammation | ||||||
| 06/14/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $31.04 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP 301-303 | Glenmark Pharmaceuticals Inc. | $13,700 | 3 |
| SEVERE PATIENTS UNCONTROLLED ON ICS 2ND CONTROLLER | Genentech, Inc. | $13,631 | 5 |
| C38072-AS-30066 | Teva Pharmaceuticals USA, Inc. | $11,361 | 5 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $10,918 | 5 |
| Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite HDM Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis | Greer Laboratories, Inc. | $7,835 | 5 |
| An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma | Teva Pharmaceuticals USA, Inc. | $6,465 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 625 | 5,716 | $138,250 | $50,915 |
| 2022 | 9 | 555 | 4,798 | $122,144 | $46,771 |
| 2021 | 8 | 498 | 4,855 | $116,633 | $46,654 |
| 2020 | 10 | 471 | 3,767 | $106,435 | $40,997 |
Total Patients
2,149
Total Services
19,136
Medicare Billing
$185,336
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 220 | $44,000 | $19,490 | 44.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 74 | 4,989 | $45,150 | $15,205 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 83 | 83 | $24,900 | $9,877 | 39.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 84 | 111 | $13,875 | $2,993 | 21.6% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 93 | 137 | $5,480 | $1,643 | 30.0% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 72 | 90 | $2,700 | $1,158 | 42.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 21 | 21 | $1,365 | $430.92 | 31.6% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 58 | 65 | $780.00 | $118.00 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 194 | $38,800 | $17,409 | 44.9% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 54 | 3,797 | $34,363 | $12,088 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 65 | 65 | $19,550 | $7,494 | 38.3% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 11 | 378 | $10,206 | $4,323 | 42.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 78 | 98 | $11,380 | $2,742 | 24.1% |
| 94664 | Evaluation of use of breathing device | Office | 2022 | 87 | 121 | $4,070 | $1,439 | 35.4% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2022 | 53 | 63 | $1,890 | $856.49 | 45.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 14 | 17 | $1,105 | $290.36 | 26.3% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2022 | 57 | 65 | $780.00 | $129.10 | 16.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 212 | $42,400 | $19,968 | 47.1% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 61 | 4,274 | $38,680 | $13,610 | 35.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 67 | 67 | $18,450 | $7,446 | 40.4% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 79 | 104 | $11,440 | $3,460 | 30.2% |
| 94664 | Demonstration and/or evaluation of patient use of aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (ippb) device | Office | 2021 | 86 | 127 | $3,810 | $1,493 | 39.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 19 | 20 | $1,100 | $369.76 | 33.6% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent, preservation free | Office | 2021 | 11 | 11 | $275.00 | $223.93 | 81.4% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2021 | 39 | 40 | $478.00 | $84.00 | 17.6% |
About Dr. Ronald Saff, MD
Dr. Ronald Saff, MD is a Allergy & Immunology healthcare provider based in Tallahassee, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528075249.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Saff, MD has received a total of $76,257 in payments from pharmaceutical and medical device companies, with $1,413 received in 2024. These payments were reported across 536 transactions from 33 companies. The most common payment nature is "" ($66,410).
As a Medicare-enrolled provider, Saff has provided services to 2,149 Medicare beneficiaries, totaling 19,136 services with total Medicare billing of $185,336. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Tallahassee, FL
- Active Since 08/02/2006
- Last Updated 06/29/2011
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1528075249
Products in Payments
- Non-Covered Product (Drug) $13,631
- CinqAir (Drug) $9,727
- Cinqair (Biological) $5,453
- ADVAIR (Drug) $2,500
- CINQAIR (Drug) $1,660
- DUPIXENT (Biological) $1,640
- CINQAIR (Biological) $1,055
- NUCALA (Biological) $933.50
- TRELEGY ELLIPTA (Drug) $573.29
- Odactra (Drug) $526.52
- FASENRA (Biological) $518.97
- Xolair (Biological) $479.59
- TEZSPIRE (Biological) $454.15
- XOLAIR (Biological) $434.05
- SPIRIVA RESPIMAT (Drug) $359.82
- STIOLTO RESPIMAT (Drug) $359.60
- BEVESPI AEROSPHERE (Drug) $339.86
- SYMBICORT (Drug) $273.15
- AIRSUPRA (Drug) $189.22
- BREZTRI (Drug) $166.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.